DiaMedica Therapeutics (DiaMedica Therapeutics) Total Payout Ratio : 0.00 (As of May. 24, 2024)

View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

DiaMedica Therapeutics's current Total Payout Ratio is 0.00.

DiaMedica Therapeutics Total Payout Ratio Historical Data

The historical data trend for DiaMedica Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Total Payout Ratio Chart

DiaMedica Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

2.34

2.20

1.90

DiaMedica Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of DiaMedica Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, DiaMedica Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Total Payout Ratio falls into.

DiaMedica Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

DiaMedica Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	36.848	+	0)	/	-19.381
	=	1.90

DiaMedica Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-5.151
	=	0.00

DiaMedica Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website

https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Executives

Jan Stahlberg	10 percent owner	C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen	officer: CFO and Secretary	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill	10 percent owner	SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls	director, officer: President and CEO	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto	10 percent owner	394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke	officer: Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt	10 percent owner	C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von	10 percent owner	TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise	10 percent owner	C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves	officer: SVP Clinical Development Oper.	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305